Top Page
Vectus Biosystems Limited
(Sydney:VBS)
Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)
Vectus Biosystems Limited Business Overview & Revenue Model
Vectus Biosystems Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 478.18K | 478.18K | 1.14M | 1.35M | 1.30M | 180.00 |
| Gross Profit | 478.18K | 478.18K | 1.14M | 1.31M | 1.28M | 1.02M |
| EBITDA | -1.69M | -1.69M | -2.27M | -3.19M | -3.28M | -3.71M |
| Net Income | -1.78M | -1.78M | -2.34M | -3.45M | -3.99M | -3.86M |
Balance Sheet | ||||||
| Total Assets | 782.66K | 782.66K | 2.03M | 4.63M | 3.94M | 6.98M |
| Cash, Cash Equivalents and Short-Term Investments | 250.99K | 250.99K | 808.97K | 2.95M | 1.28M | 5.78M |
| Total Debt | 200.00K | 200.00K | 28.93K | 70.21K | 6.90M | 8.68M |
| Total Liabilities | 1.04M | 1.04M | 539.26K | 1.11M | 8.36M | 9.88M |
| Stockholders Equity | -256.62K | -256.62K | 1.49M | 3.52M | -4.42M | -2.90M |
Cash Flow | ||||||
| Free Cash Flow | -830.09K | -830.09K | -2.10M | -2.37M | -4.46M | -3.26M |
| Operating Cash Flow | -830.09K | -830.09K | -2.03M | -2.35M | -4.44M | -3.26M |
| Investing Cash Flow | 101.03K | 101.03K | -67.90K | -17.13K | -21.00K | 0.00 |
| Financing Cash Flow | 171.07K | 171.07K | -41.28K | 4.04M | -34.55K | 6.35M |
Vectus Biosystems Limited Technical Analysis
Vectus Biosystems Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$10.67M | ― | -289.05% | ― | ― | 24.09% | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$5.68M | ― | -628.72% | ― | ― | 31.87% | |
36 Underperform | AU$6.11M | ― | -184.73% | ― | ― | 87.88% | |
27 Underperform | AU$3.21M | ― | -205.70% | ― | ― | 1.03% |
Vectus Biosystems Limited Corporate Events
Vectus Biosystems Limited has signed a binding agreement with XORTX Therapeutics Inc. for the sale of its VB4-P5 Renal Small Molecule Compound, a move that aligns with its strategy to develop and validate drug candidates for commercial partnerships. The company is also actively pursuing licensing opportunities, particularly in China, and is focused on reducing operational costs while exploring collaborations to fund further clinical studies, reflecting its commitment to advancing its anti-fibrotic therapies.
Vectus Biosystems Limited has announced its 2025 Annual General Meeting (AGM) will be held virtually on November 26, 2025. The meeting will cover several key business items, including the consideration of financial statements, the re-election of Dr. Ronald Shnier, the election of Ms. Linda Walters as directors, and the adoption of the remuneration report. The AGM provides shareholders with an opportunity to engage with the company’s leadership and discuss strategic directions, potentially impacting future company operations and stakeholder interests.
Vectus Biosystems Limited has announced the lifting of its trading suspension on the Australian Securities Exchange following a significant transaction involving a compound from its drug library. This development is expected to have a positive impact on the company’s operations and may enhance its positioning within the biotechnology sector, potentially benefiting stakeholders.
Vectus Biosystems Limited has entered into a binding agreement with XORTX Therapeutics Inc. for the sale of its VB4-P5 renal compound, which targets renal fibrosis. The transaction, valued at approximately A$4.5 million, will provide Vectus with shares and pre-funded warrants in XORTX, aligning with its strategy to develop and validate drug candidates for commercial partnerships. This deal allows Vectus to maintain an interest in the compound’s development without further financial input, while continuing to focus on its lead cardiovascular candidate and other emerging fibrosis treatments.
Vectus Biosystems Limited has voluntarily suspended its securities from trading on the ASX pending an announcement regarding a significant transaction involving one of its compounds. This suspension is intended to remain in place until October 21, 2025, or until the company makes the anticipated announcement, which could have implications for its operational strategy and market positioning.
Vectus Biosystems Limited has requested a trading halt on its securities pending an announcement regarding a significant transaction involving a compound from its drug library. This move suggests a potential strategic development that could impact the company’s market positioning and stakeholder interests, with further details expected before the resumption of trading.
Vectus Biosystems Limited has released its Corporate Governance Statement for the period from July 2024 to June 2025, highlighting its adherence to ASX corporate governance principles. The company acknowledges that while it strives to comply with these guidelines, certain recommendations are not feasible due to its size. The Board, supported by various committees, oversees governance, ensuring transparency and accountability in its operations.
Vectus Biosystems Limited has released its annual financial report, which includes consolidated financial statements and notes. The report, authorized by the Board of Directors, reflects the company’s financial activities and performance in Australian dollars, providing stakeholders with insights into its fiscal health and strategic direction.